Director/PDMR Shareholding

RNS Number : 5014F

Yourgene Health PLC

21 March 2022

 

Yourgene Health plc

("Yourgene" or the "Company")

Director Dealing

Manchester, UK - 21 March 2022: Yourgene (AIM: YGEN), a leading international molecular diagnostics group, announces that it was notified 21 March 2022 that Hayden Jeffreys, Chief Operating Officer of the Company, purchased 355,450 ordinary shares today at 8.44p per share in his SIPP account.

Following the above transaction, Hayden Jeffreys is interested in 688,944 ordinary shares in the Company, representing approximately 0.09 per cent. of the Company's issued share capital.

This announcement contains inside information for the purposes of the UK Market Abuse Regulation.
The Directors of the Company take responsibility for this announcement.

Yourgene Health plc Lyn Rees, Chief Executive Officer	Tel: [phone] [e-mail]
Barry Hextall, Chief Financial Officer
Joanne Cross, Director of Marketing
Cairn Financial Advisers LLP (NOMAD)	Tel: [phone]
Liam Murray / James Caithie / Ludovico Lazzaretti
Singer Capital Markets (Joint Corporate Broker)	Tel: [phone]
Aubrey Powell / Tom Salvesen / George Tzimas
Stifel Nicolaus Europe Limited (Joint Corporate Broker)		Tel: [phone]
Nicholas Moore / Matthew Blawat / Ben Maddison
Walbrook PR Ltd (Media and Investor Relations)	Tel: [phone] or [e-mail]
Paul McManus / Lianne Applegarth	Mob: [phone] / Mob: [phone]

About Yourgene Health

Yourgene Health is an international molecular diagnostics group which develops and commercialises genetic products and services. The group works in partnership with global leaders in DNA technology to advance diagnostic science. 

Yourgene primarily develops, manufactures, and commercialises simple and accurate molecular diagnostic solutions, for reproductive health, precision medicine and now infectious diseases. The Group's flagship products include non-invasive prenatal tests (NIPT) for Down Syndrome and other genetic disorders, Cystic Fibrosis screening tests, invasive rapid aneuploidy tests, and a recent extension into the oncology space with DPYD genotyping.

The launch of Yourgene Genomic Services has enabled Yourgene to offer a global laboratory service network equipped to be a full life-cycle partner for clinical, research and pharmaceutical organisations to support partners at the preclinical, clinical, and post-market stages to develop, manufacture, obtain regulatory approval and commercialise new products and services. In addition, Yourgene Genomic Services offers an NIPT and high throughput COVID testing service.

In August 2020, Yourgene acquired Coastal Genomics , Inc., a sample preparation technology company based in Vancouver, Canada, enabling the Company to extend its offering and IP portfolio in the DNA sample preparation sector. The acquisition increased Yourgene's geographical penetration into the US and Canada, supplementing existing coverage in the UK, Europe, MEA and Asia.

Yourgene Health is headquartered in Manchester, UK with offices in Taipei, Singapore, the US and Canada, and is listed on the London Stock Exchange's AIM market under the ticker "YGEN". For more information visit www.yourgene-health.com and follow us on twitter @Yourgene_Health.

1	Details of the person discharging managerial responsibilities / person closely associated
a)	Name	Hayden Jeffreys
2	Reason for the notification
a)	Position/status	Chief Operating Officer
b)	Initial notification /Amendment	Initial notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	Yourgene Health plc
b)	LEI	213800UUIT8BZE7QEH33
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument, type of instrument	Ordinary shares of 0.1p each
	Identification code	ISIN: GB00BN31ZD89
b)	Nature of the transaction	Purchase of ordinary shares
c)	Price(s) and volume(s)
			Price(s)	Volume(s)
			8.44p	355,450
d)	Aggregated information	N/A
	- Aggregated volume
	- Price
e)	Date of the transaction	21 March 2022
f)	Place of the transaction	UK

 

END

 

 

DSHQFLFLLXLLBBF